Dr. Natasha Leighl leads the Medical Oncology Lung Site at the Princess Margaret Centre, Toronto, Canada, where she holds the OSI Pharmaceuticals Foundation Chair. She is Professor in the Department of Medicine at the University of Toronto, Toronto, Canada and is adjunct Professor at the Institute of Health Policy Management and Evaluation, Dalla Lana School of Public Health.

Dr Leighl’s main interests are in developing new treatments in lung cancer, improving patient access to precision medicine and lung cancer patient outcomes on an international scale. She has authored or co-authored nearly 400 peer-reviewed publications and has received significant peer-reviewed grant funding. She is currently Faculty Coordinator (Metastatic Lung) for the ESMO Education Committee and leads the ESMO early stage NSCLC guideline panel. She also serves on the ASCO Thoracic Guidelines Advisory Group, CHEST early stage lung cancer guideline panel and is co-chair of the 2024 European Lung Cancer Congress. She is currently Lung Section Co-Editor of Therapeutic Advances in Medical Oncology and Deputy Editor of Critical Reviews in Oncology/Hematology. She has recently been elected to the Board of Directors of the International Association for the Study of Lung Cancer.